Telomir Pharmaceuticals Stock
Telomir Pharmaceuticals, Inc. Common Stock
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Erez Aminov
- Employees
- 2
- Market cap
- $77 M
- IPO
- 09/02/2024
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a…
Telomir Pharmaceuticals stock: price history
1D
+0.0%
1W
-6.3%
1M
-7.1%
6M
-27.6%
YTD
-21.1%
1Y
-35.2%
2Y
-78.6%
5Y
–
10Y
–
Next earnings date
Next earnings date
02/12/2026 (in 46 days)
Volatility around earnings
~3% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Telomir Pharmaceuticals
Analyst assessment of Telomir Pharmaceuticals
PRICE TARGET LOW
US$4.00
CONSENSUS
US$4.00
MEDIAN
US$4.00
PRICE TARGET HIGH
US$4.00
No current analyst ratings available.
Telomir Pharmaceuticals stock metrics
P/E
-0.69
P/B
7.17
EV/EBITDA
-12.29
RETURN ON EQUITY
-34.2%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
53.3%
FLOAT SHARES
39,218,919
AVG. DAILY VOLUME (30D)
118,241
Institutional holders
Comparable stocks
Frequently asked questions about Telomir Pharmaceuticals stock
What does Telomir Pharmaceuticals do?
Telomir Pharmaceuticals, Inc. Common Stock is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Erez Aminov, the company employs around 2 people.
The IPO was on 09/02/2024; the stock trades on NASDAQ under the ticker TELO.
What do analysts say about Telomir Pharmaceuticals stock?
The average price target is US$4.00, ranging from US$4.00 to US$4.00, with a median of US$4.00.
This is an external assessment, not a statement by Market Jury.
When does Telomir Pharmaceuticals report next?
The next earnings date is 02/12/2026.
Around past earnings, price swings were roughly 3% stronger than usual.
Does Telomir Pharmaceuticals pay a dividend?
No, Telomir Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Telomir Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Telomir Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Telomir Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.